GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » bioAffinity Technologies Inc (NAS:BIAF) » Definitions » Price-to-Free-Cash-Flow

bioAffinity Technologies (bioAffinity Technologies) Price-to-Free-Cash-Flow : N/A (As of May. 26, 2024)


View and export this data going back to 2022. Start your Free Trial

What is bioAffinity Technologies Price-to-Free-Cash-Flow?

As of today (2024-05-26), bioAffinity Technologies's share price is $2.67. bioAffinity Technologies's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.75. Hence, bioAffinity Technologies's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for bioAffinity Technologies's Price-to-Free-Cash-Flow or its related term are showing as below:

BIAF's Price-to-Free-Cash-Flow is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 26.47
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

bioAffinity Technologies's Free Cash Flow per Share for the three months ended in Mar. 2024 was $-0.24. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.75.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 5.10% per year.

During the past 4 years, bioAffinity Technologies's highest 3-Year average Free Cash Flow per Share Growth Rate was 5.10% per year. The lowest was 5.10% per year. And the median was 5.10% per year.


bioAffinity Technologies Price-to-Free-Cash-Flow Historical Data

The historical data trend for bioAffinity Technologies's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

bioAffinity Technologies Price-to-Free-Cash-Flow Chart

bioAffinity Technologies Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
- - - -

bioAffinity Technologies Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of bioAffinity Technologies's Price-to-Free-Cash-Flow

For the Diagnostics & Research subindustry, bioAffinity Technologies's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


bioAffinity Technologies's Price-to-Free-Cash-Flow Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, bioAffinity Technologies's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where bioAffinity Technologies's Price-to-Free-Cash-Flow falls into.



bioAffinity Technologies Price-to-Free-Cash-Flow Calculation

bioAffinity Technologies's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=2.67/-0.749
=N/A

bioAffinity Technologies's Share Price of today is $2.67.
bioAffinity Technologies's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.75.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

bioAffinity Technologies  (NAS:BIAF) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


bioAffinity Technologies Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of bioAffinity Technologies's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


bioAffinity Technologies (bioAffinity Technologies) Business Description

Traded in Other Exchanges
N/A
Address
22211 W Interstate 10, Suite 1206, San Antonio, TX, USA, 78257
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company is involved in developing technologies that, in the future, will be able to detect and monitor diseases of the lung and other cancers and treat many cancers.
Executives
Roby Joyce director 22211 W INTERSTATE 10, SUITE 1206, SAN ANTONIO TX 78257
Xavier Trinidad Reveles officer: Chief Operating Officer 22211 W INTERSTATE 10, SUITE 1206, SAN ANTONIO TX 78257
Michael Philip Dougherty officer: Chief Financial Officer 2934 SCATTERED OAKS ST, SAN ANTONIO TX 78232
James Michael Edwards officer: Chief Financial Officer 30907 KEENELAND DRIVE, FAIR OAKS RANCH TX 78015
Peter S Knight director 6702 STEIN CIRCLE, #642, P.O. BOX 4138, PARK CITY UT 84060
Steven Girgenti director, officer: Executive Chairman C/O HEALTHWORLD CORP, 100 AVENUE OF THE AMERICAS, NEW YORK NY 10013
Robert A. Anderson director 70 DOPPLER, IRVINE CA 92618
Gary D Rubin director, 10 percent owner 2080 NW BOCA RATON BLVD, STE 2, BOCA RATON FL 33431
Stuart Diamond director 498 SEVENTH AVE, NEW YORK NY 10018
Maria Zannes director, officer: President, CEO 19702 BELLA LOMA, #6005, SAN ANTONIO TX 78256
Harvey Sandler Revocable Trust 10 percent owner 21170 N. E. 22ND COURT, NORTH MIAMI BEACH FL 33180
Mohsin Y Meghji director C/O LOUGHLIN MEGHJI + COMPANY, NEW YORK NY 10016
Vivienne I Rebel officer: EVP, Chief Sci. & Med. Officer 8922 APACHE TRAIL, SAN ANTONIO TX 78255
Timothy P Zannes officer: Secretary, EVP, Gen. Counsel 1510 VISTA LARGA CT. NE, ALBUQUERQUE NM 87106
Nathan M Perlmutter 10 percent owner 28 PARRISH POND LANE, SOUTHAMPTON NY 11968

bioAffinity Technologies (bioAffinity Technologies) Headlines